This site is intended for healthcare professionals
Drug information

Medrone

POM
Read time: 24 mins
Last updated: 06 May 2020
Published: 24 Jul 2020

4.1 Therapeutic indications

Medrone is indicated for conditions requiring glucocorticoid activity such as:-

1. Endocrine disorders

Primary and secondary adrenal insufficiency

Congenital adrenal hyperplasia

2. Rheumatic disorders

Rheumatoid arthritis

Juvenile chronic arthritis

Ankylosing spondylitis

3. Collagen diseases/arteritis

Systemic lupus erythematosus

Systemic dermatomyositis (polymyositis)

Rheumatic fever with severe carditis

Giant cell arteritis/polymyalgia rheumatica

4. Dermatological diseases

Pemphigus vulgaris

5. Allergic states

Severe seasonal and perennial allergic rhinitis

Drug hypersensitivity reactions

Serum sickness

Allergic contact dermatitis

Bronchial asthma

6. Ophthalmic diseases

Anterior uveitis (iritis, iridocyclitis)

Posterior uveitis

Optic neuritis

7. Respiratory diseases

Pulmonary sarcoid

Fulminating or disseminated tuberculosis (with appropriate anti-tuberculous chemotherapy)

Aspiration of gastric contents

8. Haematological disorders

Idiopathic thrombocytopenic purpura

Haemolytic anaemia (autoimmune)

9. Neoplastic diseases

Leukaemia (acute and lymphatic)

Malignant lymphoma

10. Gastro-intestinal diseases

Ulcerative colitis

Crohn's disease

11. Miscellaneous

Tuberculous meningitis (with appropriate anti-tuberculous chemotherapy)

Transplantation

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).